It is important to note that iNOS is a well-established target for RA therapy, as the efficacy of two selective inhibitors—l-NIL [53] and GW274150 [54]—has already been demonstrated to prevent collagen-induced arthritis. Here, NOS2 is linked to arthritic joint disease.